Exploring host-virus interaction to improve immunotherapy against Ebola virus

Dacquin M Kasumba; John Misasi; Sabue Mulangu; Placide Mbala-Kingebeni

doi:10.1016/j.tips.2023.09.007

Exploring host-virus interaction to improve immunotherapy against Ebola virus

Trends Pharmacol Sci. 2023 Dec;44(12):857-861. doi: 10.1016/j.tips.2023.09.007. Epub 2023 Oct 14.

Authors

Dacquin M Kasumba¹, John Misasi², Sabue Mulangu³, Placide Mbala-Kingebeni⁴

Affiliations

¹ Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo; Axis of Molecular Immunology and Pathogenesis, Molecular Biology Unit, Department of Basic Sciences, Faculty of Medicine, Université de Kinshasa, Kinshasa, Democratic Republic of the Congo. Electronic address: dacquin.kasumba@unikin.ac.cd.
² National Institutes of Health, National Institute of Allergy and Infectious Diseases, Vaccine Research Center, Bethesda, MD 20892, USA. Electronic address: john.misasi@nih.gov.
³ Global Medical Affairs, Ridgeback Biotherapeutics, Miami, FL, USA. Electronic address: sabue@ridgebackbio.com.
⁴ Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo. Electronic address: mbalaplacide@gmail.com.

PMID: 37845170
DOI: 10.1016/j.tips.2023.09.007

Abstract

Recent immunological advances have led to the development of FDA-approved immunotherapies against Ebola virus (EBOV). However, patients with high viral loads have not seen as large a benefit as mild cases. Here we discuss areas of investigation that may lead to adjunctive immune therapy for patients with severe EBOV disease.

Keywords: Ebola; antibody; immune response; immunotherapy.

MeSH terms

Ebolavirus*
Hemorrhagic Fever, Ebola* / therapy
Host Microbial Interactions
Humans
Immunotherapy